Alzheimer Disease
Conditions
Brief summary
This single-center, randomized, placebo-controlled, double-blind, dose-increasing study was designed to evaluate the safety, tolerability, and pharmacokinetics of multiple successive dosing in healthy Chinese adult subjects.In this study, 20 healthy adult subjects were enrolled in a multi-dose study in the 30mg and 40mg groups.
Detailed description
In this study, subjects were given multiple doses in the corresponding dose group
Interventions
DRUGAD16 30mg、40mg
AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
DRUGAD16 Placebo 30mg、40mg
AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
Sponsors
South China Center For Innovative Pharmaceuticals
Xiangya Hospital of Central South University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
A single-center, randomized, placebo-controlled, double-blind, dose-increasing study design
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subjects were aged 18-45 years (including boundary values), male and female. 2. Weight ≥50kg (male) or ≥45kg (female), and body mass index (BMI) of 19-24kg/m2 (including the boundary values at both ends). 3. Have fully understood this study, voluntarily participated in it, and signed the Informed Consent. 4. Subjects are able to communicate well with researchers and complete the study according to protocol. 5. The subjects were deemed to be in good health based on physical examination, medical history, vital signs, electrocardiogram, chest X-ray, abdominal ultrasound, and laboratory tests. 6. Subject (including partner) is willing to have no pregnancy plan for the next 30 days (female subject) or 90 days (male subject) and is willing to use effective contraception.
Exclusion criteria
1. Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or HIV antibody. 2. The patient has symptoms or related history of any serious disease, including but not limited to heart, liver, kidney, or other acute or chronic digestive tract or respiratory tract diseases, as well as diseases of the blood, endocrine, neurological, psychiatric and other systems, or any other disease or physiological condition that can interfere with the study results. 3. A history of postural hypotension with frequent episodes. 4. A history of frequent nausea or vomiting due to any cause. 5. Any clear history of drug or food allergies, especially allergies to ingredients similar to the drugs in this study. 6. Have special dietary requirements and cannot comply with the uniform diet provided by the clinical research center. 7. Previous drug abuse history or positive urine drug screening during screening period. 8. Smokers who smoked more than 5 cigarettes a day in the 3 months before the test. 9. Heavy drinkers or regular drinkers in the 6 months prior to the study screening, who drank more than 14 units of alcohol per week (1 unit of alcohol ≈360 mL beer or 45 mL 40% spirits or 150 mL wine) or had a positive alcohol breath test during the screening period. 10. Excessive consumption of tea, coffee (more than 6 cups) and/or caffeinated beverages (more than 1L) per day. 11. Take food or drink rich in xanthine, grapefruit or alcohol, caffeine (e.g., dragon fruit, mango, grapefruit, chocolate, coffee or tea) within 48 hours before administration. 12. Surgical procedures, transfusions of blood or blood components in the month prior to study screening. 13. Blood loss or donation of more than 400 mL in the 2 months prior to screening. 14. Participated in other clinical studies and took experimental drugs within 3 months prior to study screening. 15. Study participants who had received any medication in the 28 days prior to screening. 16. Pregnant or lactating women or women who have had unprotected sex within 14 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | day-7 to day11 | The number of adverse events |
| Serious adverse events | day-7 to day11 | The number of serious adverse events |
| Number of participants with abnormal laboratory test results | Screening period (day-7 to day-2) and day11 | Laboratory tests include Blood routine, blood biochemistry, coagulation function and urine routine, etc. |
| Number of participants with abnormal vital signs | Screening period（day-7 to day-1）、days1、4、5、6、8、9 | Pulse, blood pressure, body temperature and respiratory rate were observed at different time points before and after medication. |
| Number of participants with abnormal 12-lead electrocardiogram readings | Screening period（day-7 to day-2）、days1、6、11 | Abnormal12-lead electrocardiogram |
| Number of participants with abnormal physical examination findings | Screening period（day-7 to day-2）、days11 | The skin, mucosa, lymph nodes, head, neck, chest, abdomen, spine/limbs and nervous system were observed at different time points before and after medication. |
| Concomitant medication | Up to day 11 | Any concomitant medication |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| λz of AD16 | Up to day 11 | Terminal disposition rate constant/terminal rate constant |
| AUC 0-48h of AD16 | Up to day 11 | Area under the plasma concentration-time curve from time zero to time 48h |
| AUC_%Extrap of AD16 | Up to day 11 | AUC\_%Extrap is residual area percentage |
| Tmax,ss of AD16 | Up to day 11 | Time to reach the maximum (peak) plasma concentration following drug administration at steady state |
| Cmax, ss of AD16 | Up to day 11 | Maximum (peak) steady-state plasma drug concentration during a dosage interval |
| Cavg,ss of AD16 | Up to day 11 | Cavg,ss is the steady-state mean concentration |
| t1/2,ss of AD16 | Up to day 11 | Elimination half-life（steady state ） |
| Tmax of AD16 | Up to day 11 | Time to reach the maximum (peak) plasma concentration following drug administration |
| AUC 0-48h,ss of AD16 | Up to day 11 | Area under the plasma concentration-time curve from the last dose to 48 h |
| AUC 0-∞,ss of AD16 | Up to day 11 | The area under the plasma concentration-time curve is extrapolated from the last dose to infinity |
| CL/F,ss of AD16 | Up to day 11 | CL/F is defined as the ratio of total clearance(CL) to bioavailability(F)（steady state ） |
| Rac of AD16 | Up to day 11 | Rac is accumulation ratio |
| DF of AD16 | Up to day 11 | Degree of fluctuation（DF）Percentage fluctuation in steady state = 100 × (Cmax,ss -Cmin,ss)/Cavg,ss |
| Vd/F,ss of AD16 | Up to day 11 | Apparent volume of distribution after non-intravenous administration （steady state ） |
| AUC 0-τ,ss of AD16 | Up to day 11 | The area under the plasma concentration-time curve during a dosing interval at steady state |
| Cmax of AD16 | Up to day 11 | Maximum (peak) plasma drug concentration |
| t1/2z of AD16 | Up to day 11 | Elimination half-life (to be used in a one-compartment or noncompartmental model) |
| AUC 0-∞ of AD16 | Up to day 11 | Area under the plasma concentration-time curve（AUC） from time zero to infinity |
| AUC 0-t of AD16 | Up to day 11 | Area under the plasma concentration-time curve（AUC） from time zero to time t |
| Vd/F of AD16 | Up to day 11 | Apparent volume of distribution after non-intravenous administration |
| CL/F of AD16 | Up to day 11 | CL/F is defined as the ratio of total clearance(CL) to bioavailability(F). |
Countries
China
Outcome results
None listed